Acumapimod

Acumapimod (BCT197) is an orally active p38 MAP kinase inhibitor, with an IC50 of less than 1 μM for p38α.

Product Specifications

CAS Number

[836683-15-9]

Product Name Alternative

BCT197

UNSPSC

12352005

Hazard Statement

H315, H317, H318, H334, H335, H341, H361, H370, H413

Target

Autophagy; p38 MAPK

Type

Reference compound

Related Pathways

Autophagy; MAPK/ERK Pathway

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Acumapimod.html

Concentration

10mM

Purity

99.68

Solubility

DMSO : ≥ 50 mg/mL

Smiles

O=C(NC1CC1)C2=CC=C(C)C(N3N=CC(C(C4=CC=CC(C#N)=C4)=O)=C3N)=C2

Molecular Formula

C22H19N5O2

Molecular Weight

385.42

Precautions

H315, H317, H318, H334, H335, H341, H361, H370, H413

References & Citations

[1]Norman P, et al. Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2015 Mar;24 (3) :383-92.|[2]De Buck S, et al. Population PK-PD Model for Tolerance Evaluation to the p38 MAP Kinase Inhibitor BCT197. CPT Pharmacometrics Syst Pharmacol. 2015 Dec;4 (12) :691-700.